Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated May 20, 2003, reports on the Annual General Meeting held on May 19, 2003. The meeting approved the financial statements for the fiscal year ended December 31, 2002, and addressed corporate governance updates and forward-looking guidance for 2003.
Key Financial Metrics
- Net Profit (2002): 1,758 million euros (attributable to the Group, before exceptional items and goodwill amortization).
- Earnings Per Share (2002): 2.42 euros.
- Dividend: 0.84 euro per share (payable June 2, 2003).
- Revenue, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for total revenue, operating cash flow, total debt, or liquidity ratios for the reporting period.
Material Changes Versus Prior Period
- Net Profit Growth: Increased by 28% compared to the prior year (before exceptional items and goodwill amortization).
- Earnings Per Share Growth: Increased by 29% compared to the prior year.
- Dividend Increase: The approved dividend represents a 27% increase over the previous year.
Guidance, Outlook, and Risks
Management confirmed forecasts for 2003 based on first-quarter sales performance. The outlook includes:
- Sales Growth: Expected to be at a similar level to 2002 on a comparable basis.
- Earnings Per Share: Projected to increase close to 20% (before exceptional items and goodwill amortization), assuming an exchange rate of one euro per dollar. Management noted a sensitivity of 1% growth for every 3-cent movement in the dollar exchange rate.
- Key Drivers: Growth is expected from Plavix, Aprovel, Ambien, Arixtra, and Eloxatin, pending the US registration of Xatral o.d. by the end of 2003.
- Risks and Contingencies: Forward-looking statements are subject to uncertainties including US market expansion profitability, R&D success, intellectual property protection, and healthcare reimbursement/pricing reforms in the US and France.
Investor Verification Checklist
- Verify the exact consolidated sales figures for 2002 and Q1 2003 to confirm the "similar level of growth" guidance.
- Monitor the EUR/USD exchange rate, as earnings guidance is highly sensitive to currency fluctuations.
- Confirm the regulatory status and expected approval timeline for Xatral o.d. in the United States.
- Review the full 2002 annual report (Form 20-F) for detailed revenue, cash flow, and debt metrics not included in this summary.